Targeting B cell malignancies through human B cell receptor specific CD4 T cells

BackgroundThe B cell receptor (BCR) expressed by a clonal B cell tumor is a tumor specific antigen (idiotype). However, the T cell epitopes within human BCRs which stimulate protective immunity still lack detailed characterization.MethodsIn this study, we identified 17 potential CD4 T cell peptide e...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal for immunotherapy of cancer 2015-11, Vol.3 (Suppl 2), p.P59-P59, Article P59
Hauptverfasser: Weng, Jinsheng, Baio, Flavio Egidio, Moriarty, Kelsey, Torikai, Hiroki, Wang, Hua, Liu, Zhiqiang, Maiti, Sourindra, Gwak, Dongho, Popescu, Michael, Cha, Soung-chul, Neelapu, Sattva S, Kwak, Larry
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BackgroundThe B cell receptor (BCR) expressed by a clonal B cell tumor is a tumor specific antigen (idiotype). However, the T cell epitopes within human BCRs which stimulate protective immunity still lack detailed characterization.MethodsIn this study, we identified 17 potential CD4 T cell peptide epitopes derived from BCR heavy and light chain variable region sequences. Detailed analysis revealed these CD4 T cell epitopes stimulated Th1 CD4 T cells to directly recognize the autologous tumors by secretion of IFN-γ, indicating the epitopes are processed and presented by tumors.ResultsOne BCR peptide-specific CD4 T cell line was also cytotoxic and lysed autologous tumor cells through the perforin pathway. Sequence analysis of the epitopes revealed 10 were potentially shared by multiple primary patients' tumors, and 16 had the capacity to bind more than one HLA DRB1 allele. T cells stimulated by shared epitopes recognized primary tumors expressing the same sequences on different HLA DRB1 alleles.ConclusionsIn conclusion, we identified multiple BCR-derived CD4 T cell epitopes with promiscuous HLA binding that are shared by up to 36% of patients, suggesting a strategy to overcome the requirement for individual preparation of therapeutic agents targeting idiotype.
ISSN:2051-1426
2051-1426
DOI:10.1186/2051-1426-3-S2-P59